tirzepatide for the treatment of obstructive sleep apnea and obesity In a prespecified secondary analysis SURMOUNT-OSA trial it was found that improves cardiometabolic outcomes in patients with moderate-to-severe OSA Tirzepatide (Zepbound) – A New
Description
doi: 10.2337/dc19-0449
Several medical publications have suggested that GLP-1 agonists can assist with the conversion of white fat to brown fat - which is the fat we have in greater quantities in our youth and is more metabolically active and rich in mitochondria
Next Steps: Prices for glp-1 medications have dropped significantly, and there are now many FDA-approved options
"Natural GLP-1 alternative" without clinical data is marketing, not science
Together, these mechanisms lower the workload on the heart and improve blood flow efficiency, independent of any weight reduction
Healthcare providers should use the most specific E66 subcode supported by the clinical record
